Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: A phase II clinical study

Giammaria Fiorentini, Susanna Rossi, Patrizia Dentico, Paolo Bernardeschi, Alessandra Calcinai, Francesco Bonechi, Maurizio Cantore, Stefano Guadagni, Michele De Simone

Research output: Contribution to journalArticlepeer-review

Abstract

Aims and background: The advantage of delivering chemotherapy by hepatic arterial infusion is the acquisition of a high concentration of the drug in the target. Irinotecan (CPT-11) is active for the treatment of advanced colorectal cancer. In phase I studies, doses of 20 mg/m2/d for 5 days given every 4 weeks as continuous infusion or 200 mg/m2 as a short 30-min infusion given every 3 weeks is recommended for phase II studies. Methods and study design: Twelve patients with a median liver substitution of 30% (20-50%) were enrolled, 6 progressed after a FOLFOX-induced partial response and 6 progressed after 5-fluorouracil and folinic acid. All patients had a surgically (n = 6) or angiographically placed port (n = 6). They received hepatic arterial infusion chemotherapy with CPT-11 (200 mg/m2) on an out-patient basis, every 3 weeks as a short 30-min infusion for six cycles. Results: Four partial responses were observed (33%) lasting 24, 15, 12 and 8+ weeks, 3 stable disease (25%) lasting more than 12 weeks, and 5 progressions (41%). Six patients (50%) presented a >30% reduction in CEA. Toxicity was G2 diarrhea in 5 patients (41%) and G2 myelosuppression in 6 (50%); one patient had abdominal right upper quadrant pain requiring analgesics. Conclusions: CPT-11 is active as hepatic arterial infusion chemotherapy in liver metastases from colorectal cancer and can rescue systemically pretreated patients. Our schedule seems safe, feasible and well accepted on an out-patient basis.

Original languageEnglish
Pages (from-to)382-384
Number of pages3
JournalTumori
Volume89
Issue number4
Publication statusPublished - Jul 2003

Keywords

  • Colorectal cancer
  • Hepatic arterial infusion chemotherapy
  • Irinotecan
  • Liver metastases

ASJC Scopus subject areas

  • Cancer Research

Fingerprint

Dive into the research topics of 'Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: A phase II clinical study'. Together they form a unique fingerprint.

Cite this